Optimization of a self antigen for presentation of multiple epitopes in cancer immunity - Wikidata - awgldk - TriplyDB

Optimization of a self antigen for presentation of multiple epitopes in cancer immunity

Optimization of a self antigen for presentation of multiple epitopes in cancer immunity

http://www.wikidata.org/entity/Q34537491

about

Exploiting the Immunogenic Potential of Cancer Cells for Improved Dendritic Cell Vaccines New perspectives on the role of vitiligo in immune responses to melanoma Processing of tumor antigen differentially impacts the development of helper and effector CD4+ T-cell responses Broad antigenic coverage induced by vaccination with virus-based cDNA libraries cures established tumors Using virally expressed melanoma cDNA libraries to identify tumor-associated antigens that cure melanoma.Development of effective vaccines for old mice in a tumor model.Immunization delivered by lentiviral vectors for cancer and infectious diseases.Interferon γ limits the effectiveness of melanoma peptide vaccines.Development of tumor-infiltrating CD8+ T cell memory precursor effector cells and antimelanoma memory responses are the result of vaccination and TGF-β blockade during the perioperative period of tumor resection The effect of adjuvanting cancer vaccines with herpes simplex virus glycoprotein D on melanoma-driven CD8+ T cell exhaustion Lentivector immunization stimulates potent CD8 T cell responses against melanoma self-antigen tyrosinase-related protein 1 and generates antitumor immunity in mice.Enhanced responses to tumor immunization following total body irradiation are time-dependent Mechanisms of immunization against cancer using chimeric antigens.Variable epitope library carrying heavily mutated survivin-derived CTL epitope variants as a new class of efficient vaccine immunogen tested in a mouse model of breast cancer.A pilot study with a therapeutic vaccine based on hydroxyapatite ceramic particles and self-antigens in cancer patients NKG2D signaling on CD8⁺ T cells represses T-bet and rescues CD4-unhelped CD8⁺ T cell memory recall but not effector responses Cross-presentation of glycolipid from tumor cells loaded with alpha-galactosylceramide leads to potent and long-lived T cell mediated immunity via dendritic cells.Dendritic cells enhance the activity of human MUC1-stimulated mononuclear cells against breast cancer.BiVax: a peptide/poly-IC subunit vaccine that mimics an acute infection elicits vast and effective anti-tumor CD8 T-cell responses.HSP70i is a critical component of the immune response leading to vitiligo Recombinant lentivector as a genetic immunization vehicle for antitumor immunity.Cytomegalovirus-based cancer vaccines expressing TRP2 induce rejection of melanoma in mice.Indoleamine 2,3-dioxygenase controls conversion of Foxp3+ Tregs to TH17-like cells in tumor-draining lymph nodes.Self-antigen-specific CD8+ T cell precursor frequency determines the quality of the antitumor immune response.CCL22 to Activate Treg Migration and Suppress Depigmentation in Vitiligo Improved tumor immunity using anti-tyrosinase related protein-1 monoclonal antibody combined with DNA vaccines in murine melanoma Novel toll-like receptor 2 ligands for targeted pancreatic cancer imaging and immunotherapy.Melanoma-associated antigen expression in lymphangioleiomyomatosis renders tumor cells susceptible to cytotoxic T cells.Mutant HSP70 reverses autoimmune depigmentation in vitiligo.Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses.Tyrosinase related protein 1 (TYRP1/gp75) in human cutaneous melanoma.Thymic involution: where endocrinology meets immunology.Active immunotherapy: current state of the art in vaccine approaches for NHL Engineering α-fetoprotein-based gene vaccines to prevent and treat hepatocellular carcinoma: review and future prospects.A Novel DNA Vaccine Platform Enhances Neo-antigen-like T Cell Responses against WT1 to Break Tolerance and Induce Anti-tumor Immunity.Novel immunotherapies for the treatment of melanoma.Combination of lentivector immunization and low-dose chemotherapy or PD-1/PD-L1 blocking primes self-reactive T cells and induces anti-tumor immunity.Retention of immunogenicity produced by mucin 1 peptides with glycosylation site substitutions.An optimized peptide vaccine strategy capable of inducing multivalent CD8(+) T cell responses with potent antitumor effects.Impact of sequence variation in a dominant HLA-A*02-restricted epitope in hepatitis C virus on priming and cross-reactivity of CD8+ T cells

P2860

Q26772715-E9FB5E9E-0CD8-4903-B1D5-F6726B82F1AF Q26996799-A6CFDFD6-053B-4B58-9400-42DEC29BE9D7 Q33930126-88CFD1D6-5D19-489F-9813-78F2A3273722 Q33936327-B27D688D-0667-4577-B672-7918AAD11ECB Q34198856-950A24A2-A166-4300-9026-B15CE2E40E17 Q34501086-6463416F-E540-4201-B36A-A2A9258E27E6 Q34539879-639DE1AE-54B7-4A10-8602-80A724F2D6E3 Q34568835-BF5E9EB8-E1D4-470B-9312-4D1D2F5F6E55 Q34625208-174283E6-F235-4E5D-8968-557F0A767218 Q34626229-6BBD786C-7630-4CB0-907C-6CE32A9FACFD Q34801323-13D9522E-3632-48A6-8533-7B9E7BA70E78 Q35070312-0B0DF667-333A-4377-A4ED-36FA5FE4A97E Q35442846-1FFF6356-B253-4A2C-80A3-8AFEAF866BD0 Q35498335-02C4BBDD-4B26-47FA-ABF8-B12366608386 Q35753007-9BBA30C1-881E-476B-BDF6-DA9E7F75CD9B Q36215821-47087363-A9E5-430E-AF5B-A616F7E583CA Q36229067-3DD9652B-D00F-4B53-8B25-0388F9E96260 Q36694948-45F6C4F0-CCF2-407E-87C2-5036B84393F6 Q36763266-1E8175D6-AAD0-43E2-A1B1-83B546F2B958 Q36871508-00DF490B-A5A2-4B07-B884-9F2CAAFDDF99 Q37123441-1D3B4AFE-D033-4EA3-8379-F05DD51C3C22 Q37129222-988D6B9E-D68E-4EC3-B76B-4466A9486038 Q37234611-1BBF12AD-D3FA-4C5C-B8A3-07197177EDD9 Q37273315-4AB77D9A-4882-45E2-B98F-A0FDE33A17EB Q37299737-843DB567-C866-415C-9EF6-0333F8275CCF Q37342888-64074B5E-EB9D-4E29-B82F-B6FA7F69F28D Q37389360-07F1670F-EFE5-4FF4-BD3F-3354C2380C37 Q37462768-83350A1C-8DD3-42E8-A9BC-CC327AE760BC Q37551330-982A425A-391C-4DF8-A1CB-AAFD4AAA81D0 Q37554718-A6D0CDBB-23FF-4BF8-A3F4-87C7DFCC12C8 Q37842937-A9AA2D91-C402-4AB1-8E09-A3D64EA18B56 Q37939600-9E609EF1-D894-49B4-B56F-BDFC4D1017D2 Q38030484-EC66EBE5-D5E9-4AB9-AA74-DC716B31647F Q38231581-6C5846E6-3C47-4180-8190-51889CDA6C95 Q38714821-61E8FC71-5283-45AE-97D3-1FDF0672F890 Q38824190-25CA089C-2545-42B9-AE9C-83227535F257 Q39549328-D5200CAD-948C-4A13-96D9-F0BE72465916 Q39703930-BB5EAE1B-4938-4CC6-AEC2-C37AFE838D76 Q41242778-3572EFD5-8720-4B2B-91C5-AAED02010870 Q41893704-FC5E16FB-7836-4718-A5E7-CB291A80D9BA

P2860

Optimization of a self antigen for presentation of multiple epitopes in cancer immunity

http://www.wikidata.org/entity/Q34537491

description

2006 nî lūn-bûn

@nan

2006 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Optimization of a self antigen for presentation of multiple epitopes in cancer immunity

@ast

Optimization of a self antigen for presentation of multiple epitopes in cancer immunity

@en

Optimization of a self antigen for presentation of multiple epitopes in cancer immunity

@nl

type

label

Optimization of a self antigen for presentation of multiple epitopes in cancer immunity

@ast

Optimization of a self antigen for presentation of multiple epitopes in cancer immunity

@en

Optimization of a self antigen for presentation of multiple epitopes in cancer immunity

@nl

prefLabel

Optimization of a self antigen for presentation of multiple epitopes in cancer immunity

@ast

Optimization of a self antigen for presentation of multiple epitopes in cancer immunity

@en

Optimization of a self antigen for presentation of multiple epitopes in cancer immunity

@nl

P1433

Q34537491-5FB44819-1B04-4E3C-8418-0C4E42031307

P1476

Q34537491-C44C3D8D-1886-4C49-A759-582CA8CCBBF4

P2093

Q34537491-02E1D79C-EFCE-411F-B5FF-C57732C9CD0D

Q34537491-0373FDD8-0781-45CD-A4FB-BDFE65E2F556

Q34537491-2764892C-772D-4F4B-B345-5D64DF886C77

Q34537491-28192321-B9BF-4C89-A809-81BB52E3C95E

Q34537491-2F6FFFA7-8A19-471E-8A83-490D1310E51A

Q34537491-6EA82381-D7F8-47D2-B8FF-94DB6BBDFB21

Q34537491-7BD6F5C4-4ABD-4829-B834-FC166D1BED5F

Q34537491-83FDD22C-5949-4FC2-9F9C-8B7712BDE682

Q34537491-B254B3DC-88EB-4766-9E89-875CB4A9CAD0

Q34537491-B354B832-BEF2-4765-87AF-CA9CE65B3B56

P2860

Q34537491-05CD44A3-3180-44AB-8279-27C275FFB80B

Q34537491-09DB14C4-4ADA-4C41-B3D1-E75B8FD297A3

Q34537491-201FFACF-01FC-41E5-9101-00D0F18D96D3

Q34537491-2441A782-A788-41E5-9942-E0523D050E47

Q34537491-2B96EA01-949D-4777-85BC-33F6D6B80F53

Q34537491-30E24D03-0D18-49DB-9F71-67CF7CFCE09C

Q34537491-35A00C6D-B2DA-4347-9C79-DC9A707FEA94

Q34537491-36D2C59C-E14E-41CD-AD22-53F4026297FD

Q34537491-373F8FDD-964A-4ADC-B75D-CB20BC9A53D7

Q34537491-3C6F1CFC-4B9E-4C92-8A22-DBCDD2FFF9B0

P304

Q34537491-B9960A80-4406-4201-9AF3-51BE9BE93503

P31

Q34537491-53B5D97C-3B5C-4DF2-B56B-D16BC07C1ACA

P356

Q34537491-490D6ABB-8B62-4737-A2E9-A8F14157D849

P407

Q34537491-04EF4F3D-0E7B-4B38-9E20-74C1E8E76D15

P433

Q34537491-8C76E797-46DC-4EF1-BF17-280F10037B79

P478

Q34537491-59D4A4DD-DE7D-4FB8-AD88-A5EB969E79F8

P577

Q34537491-291A5052-803D-48CB-88E1-60380E1967EC

P698

Q34537491-BE7E22C0-6A90-420F-95BC-3CE6C57108F3

P932

Q34537491-58FA1EE1-447E-4129-ACDB-DEA5E1422AB0

P356

P1433

Journal of Clinical Investigation

P1476

Optimization of a self antigen for presentation of multiple epitopes in cancer immunity

@en

P2093

Adam D Cohen

http://www.w3.org/2001/XMLSchema#string

Alan N Houghton

http://www.w3.org/2001/XMLSchema#string

Cailian Liu

http://www.w3.org/2001/XMLSchema#string

Fei Duan

http://www.w3.org/2001/XMLSchema#string

Gabrielle Rizzuto

http://www.w3.org/2001/XMLSchema#string

Jedd D Wolchok

http://www.w3.org/2001/XMLSchema#string

José A Guevara-Patiño

http://www.w3.org/2001/XMLSchema#string

Manuel E Engelhorn

http://www.w3.org/2001/XMLSchema#string

Mary Jo Turk

http://www.w3.org/2001/XMLSchema#string

Taha Merghoub

http://www.w3.org/2001/XMLSchema#string

P2860

The qualitative nature of the primary immune response to HIV infection is a prognosticator of disease progression independent of the initial level of plasma viremia

Natural selection of tumor variants in the generation of "tumor escape" phenotypes

The melanoma antigen gp75 is the human homologue of the mouse b (brown) locus gene product

Broad Specificity of Virus-Specific CD4+ T-Helper-Cell Responses in Resolved Hepatitis C Virus Infection

Functional and genomic analyses reveal an essential coordination between the unfolded protein response and ER-associated degradation

The use of HLA-A*0201-transfected K562 as standard antigen-presenting cells for CD8(+) T lymphocytes in IFN-gamma ELISPOT assays

Pseudomonas exotoxin-mediated delivery of exogenous antigens to MHC class I and class II processing pathways.

Regulated folding of tyrosinase in the endoplasmic reticulum demonstrates that misfolded full-length proteins are efficient substrates for class I processing and presentation.

Broad, intense anti-human immunodeficiency virus (HIV) ex vivo CD8(+) responses in HIV type 1-infected patients: comparison with anti-Epstein-Barr virus responses and changes during antiretroviral therapy.

Elicitation of high-frequency cytotoxic T-lymphocyte responses against both dominant and subdominant simian-human immunodeficiency virus epitopes by DNA vaccination of rhesus monkeys

P304

1382-1390

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1172/JCI25591

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

116

http://www.w3.org/2001/XMLSchema#string

P577

2006-04-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16614758

http://www.w3.org/2001/XMLSchema#string

P932

1435720

http://www.w3.org/2001/XMLSchema#string